BIOTECHNOLOGY DEVELOPMENT COSTS TOP $1.2 BILLION PER PRODUCT
The average cost of developing a new therapeutic biotechnology product is more than $1.2 billion, including the costs of drugs that fail in testing and the time associated with bringing these products to market, according to a new study by the Tufts Center for the Study of Drug Development.
The study's authors defined a biotechnology product as "any therapeutic biological compound, including recombinant proteins, monoclonal and polyclonal antibodies, antisense oligonucleotides, therapeutic genes and recombinant and DNA vaccines," as distinguished from "traditional" pharmaceuticals.
The $1.2 billion figure includes an average out-of-pocket cash cost of $198 million for preclinical development, which rises to $615 million when fully capitalized, and an average out-of-pocket cash cost of $361 million for clinical development, which rises to $626 million when fully capitalized.
Capitalization increases biopharmaceutical costs relative to traditional pharmaceutical costs because of a longer development timeline and a higher cost of capital, the study found. A new biotech product takes 97.7 months on average to make its way through clinical development and regulatory review, about 8 percent longer than for traditional pharmaceuticals. On the other hand, biopharmaceuticals have an overall clinical approval success rate of 30.2 percent, as opposed to 21.5 percent for traditional drug pipelines.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct